If a fund sells an asset to itself to prove the value is real, is the value real or only the need for time? Continuation vehicles promise flexibility and alignment. They also reveal a deeper fragility: when exits dry up, private equity manufactures its own liquidity and hopes the cycle cooperates. Hope is not a strategy. Time can heal, but it also compounds risk.
The rise of continuation vehicles is framed as progress. Hold winners longer, give existing investors a choice, bring in fresh capital, avoid a bad auction in a bad market. In 2020, one mid-market firm asked to keep a regional urgent care chain longer than planned; investors agreed. That decision looked prudent during lockdowns. This template spread across the industry. But the structure is not neutral. It is an inside sale with layered fees, optionality for the general partner, and embedded adverse selection.
Game theory teaches that informed sellers do not sell good assets cheaply to uninformed buyers. They sell the assets that require narrative and time. In GP-led secondaries, the GP is both seller and buyer. That can work when returns are obvious and financing is cheap. It becomes fragile when rates rise, cash flows decelerate, and valuations rely on future roll-ups. The inside sale is a pressure vessel; small cracks propagate when stress persists.
Liquidity is a market property, not a rights claim. Continuation vehicles create a buyer when the buyer pool is shallow. That is a form of financial engineering. In engineering, a bridge can carry more load with temporary bracing, but fatigue accumulates. Continuation capital braces balance sheets and marks. It also extends the timeline of truth. The longer you defer true price discovery, the sharper it becomes when it arrives.
Consider a portfolio company moved into a $660 million continuation fund in 2019. Earnings later fell. Expected returns were revised down. Its secured loan due in 2026 traded near 83 cents on the dollar. That is not a theoretical concern; it is a market signal of stress, refi risk, or both. If a continuation vehicle needs continuation capital of its own—a CV squared—the cure starts to look like the disease.
Healthcare was supposed to be non-cyclical. It is not non-financial. The past decade rewarded roll-ups in physician practices, urgent care, and software. Leverage subsidized buy-and-build models. Now exits are harder. An attempt to sell a healthcare analytics provider for more than a billion stalled. Efforts to offload assets like health insurance software and employer clinics are taking longer. These are not isolated anecdotes. They are base-rate reminders: when rates are high and buyers thin, even resilient sectors face bottlenecks.
Healthcare roll-ups carry integration risk and reimbursement risk. Add higher interest expense and the margin for error narrows. A continuation vehicle does not lower debt service, fix staffing, or speed up payer approvals. It buys time. In option language, it buys time value. If asset drift is mediocre and volatility rises, more time increases default probability. Merton taught that with longer horizons, weak balance sheets become equity-like. The narrative of patience can become a math problem.
The lemons problem is not a slur; it is a statistical fact. Sellers keep the assets where their private information favors them. If you can exit your best businesses at premium multiples to strategic buyers, you do that. You roll the rest. Over time, the continuation funnel skews toward assets that need internal support. That does not mean all continuation deals are bad. It means the portfolio is not random.
Sophisticated limited partners know this. They ask for independent fairness opinions, LP advisory committee approvals, and third-party price discovery. Yet governance is a weak substitute for a real market. The GP has an incentive to avoid a punitive mark and keep fee streams alive. The LP has an incentive not to force a markdown that triggers a cascade across funds. In repeated games, reputational equilibrium can keep everyone in line—until one player defects. When a few continuation assets stumble, the whole structure reprices.
Private equity lives with appraisal risk. That is accepted. But continuation vehicles stack layers of appraisal on top of appraisal. A company enters a continuation fund at a price set by a process the sponsor influences. Debt markets do not always agree. Loans trade at discounts, signaling higher required returns. Equity marks that lag debt marks are not unique to private equity, but the lag is longer when ownership is locked inside the same sponsor ecosystem.
Opacity begets fragility. Investors anchor on smooth net asset values. They design liquidity around quarterly marks that move slowly. That works until it does not. We saw a version of this in 2007 with structured investment vehicles, and after 2009 with extend-and-pretend banks. Delayed recognition does not eliminate loss. It reallocates it over time and across investors. Continuation funds, especially in size and sequence, can turn mark-to-model comfort into a systemic shock absorber that fails when the load is largest.
Extending hold periods is not inherently reckless. Many businesses benefit from compounding under stable ownership. But duration is a risk factor. The longer the horizon, the more regime shifts you must survive. Rates, regulation, input costs, competition—any one can reprice the thesis. In nature, suppressing small fires builds deadwood. When the spark finally lands, the blaze is larger. Continuation vehicles suppress the small fires of honest exits and hard marks. They can turn a manageable loss into a capital event.
There is also the fee geometry. Longer holds mean more management fees. Secondary transactions can crystalize carry on old assets and reset it on new ones. Stapled deals bring fresh commitments. None of this is illegal or even uncommon. But incentives shape behavior at the margin. When avoiding a down exit preserves both economics and optics, more assets will be rolled. That is a predictable response, and it raises the fragility of the system.
The default framing is headline valuation and sector narrative. Replace it with structure and probability. Ask: What is the true buyer universe for this asset today? What do the debt markets say? How many degrees of freedom are left before covenants or cash burn force action? What is the base rate of success for roll-ups facing higher funding costs? If a continuation vehicle is required, what is the plan for exit that does not rely on another internal buyer?
Investors should price the lemons premium. They should require larger discounts or stronger protections on GP-led deals. They should treat smooth marks as a signal to increase, not relax, skepticism. And they should read a loan price at 83 as information, not noise. In a war of attrition between valuation and cash flow, cash flow wins.
Continuation vehicles are not the villain. They are a tool. But tools used to avoid pain invite larger pain later. Markets are ecosystems. Tight credit, sticky valuations, and engineered liquidity can coexist for a while. Then a catalyst—failed refinance, regulatory change, a hiccup in reimbursement—tests the weakest links. The story here is not one firm or one asset. It is the slow build of hidden fragility across a structure that looks steady because it is designed to look steady. Stability earned by suppression is not resilience. It is a bridge with too much traffic and too few inspections.
